Today, Bruce Campbell (2) commented about whether DFY.TO, AGF.B.TO, CDR.TO, KXS.TO, ALM, NEO.TO, GRN.TO, QNC.V, CCO.TO, TVE.TO, WELL.TO, PRL.TO, ATD.TO, ANRG.TO, TNZ.TO, MDA.TO, APTX.TO, GRID.TO, AVN.V, CVVY.TO, BOIL.CN, PNG.V, ABXX-NE, ATZ.TO are stocks to buy or sell.
We've seen a lot of rotation in the last 30-45 days. Tech was where most investors were crowded into, and now the air is really coming out of that sector while other sectors are starting to move. US healthcare is really making moves, as are US financials (Canadian ones have been doing that for some time). Sector breadth is broadening as investors look for returns.
His team trimmed its tech exposure over the last month. They're not moving out of the sector entirely. There's often rotation inside the sector itself -- software stocks were beaten up in the first quarter, and now some are coming back to life. At the same time, chips and semis are losing some steam.
He's looking at anything under ~$5B in Canadian industrials and technology that's been left for dead in the summer, a not-unusual occurrence when volumes dry up. Yet the fundamentals on a lot of them have been extremely strong. If they continue to execute from a business standpoint, the stock price should follow.
His firm follows top-down indicators, and these are all still positive across all market caps. Seeing rotation into different sectors. If you project where growth is going to be, and where inflation is going, it looks as though the fall could set up quite nicely especially with the earnings expected in the next few months. It should all have a positive impact for the markets.
Short report got catalysts going to the downside, pointing to volumes being due to market-making activity. Management says this is normal when you start up an exchange. Technology of digital settlement of futures contracts improves the process.
He sold, as it broke down on technicals. Likes it, watching closely to get back in.
Looks impressive, but he likes a bit more trading history before jumping in. (Interestingly, the IPO came out just before SpaceX, and APTX has outperformed it.) Seeing amazing growth, as well as projected growth. Moving beyond generics to biosimilars (take long to be approved, not as much risk, margins tend to be higher). Expanding to US and beyond.